The National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “Catalogue of Drugs for National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance” and the “Catalogue of Innovative Drugs for Commercial Health Insurance”. Among them, it is proposed to actively promote the entry of new drugs into hospitals. Health insurance departments in each province should work with relevant departments to guide designated medical institutions to properly prepare and use the drugs listed in the catalogue. Strengthen agreement management with designated medical institutions for medical insurance, medical institutions with work-related injury insurance agreements, and agencies with work-related injury rehabilitation agreements, and include requirements relating to the rational preparation and use of drugs included in the medical insurance catalogue into agreements. When determining the 2026 fund expenditure budget, each region should fully consider the catalogue adjustment factors. For cases where innovative drugs within the medical insurance catalogue are used rationally, medical institutions are supported to independently report individual cases for which payment is inappropriate according to disease type standards. Local health insurance departments should simplify procedures and optimize procedures, organize experts to review individual special cases on a quarterly or monthly basis, and implement project-based payments or adjust payment standards for the relevant cases based on the review results. Designated medical institutions, medical institutions with work-related injury insurance agreements, and work-related injury rehabilitation agreement agencies should, in principle, hold a pharmaceutical council meeting before the end of February 2026 to promptly adjust drug supplies or establish temporary procurement green channels as needed to protect clinical diagnosis and treatment needs and patients' rights to use medication rationally. According to the requirements of the “Certain Measures” and “Notice on Adapting to the Normalization of National Health Insurance Negotiations and Continuing to Accomplish the Implementation of Negotiated Drugs”, negotiated drugs may not be subject to “one product, two regulations”, and must not influence the implementation of negotiated drugs on the grounds of total medical insurance limits, restrictions on the number of drugs used in medical institutions, etc. All regions are encouraged to take active measures to promote negotiated drugs and connect them with designated pharmaceutical institutions.

The National Health Insurance Administration and the Ministry of Human Resources and Social Security issued the “Catalogue of Drugs for National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance” and the “Catalogue of Innovative Drugs for Commercial Health Insurance”. Among them, it is proposed to actively promote the entry of new drugs into hospitals. Health insurance departments in each province should work with relevant departments to guide designated medical institutions to properly prepare and use the drugs listed in the catalogue. Strengthen agreement management with designated medical institutions for medical insurance, medical institutions with work-related injury insurance agreements, and agencies with work-related injury rehabilitation agreements, and include requirements relating to the rational preparation and use of drugs included in the medical insurance catalogue into agreements. When determining the 2026 fund expenditure budget, each region should fully consider the catalogue adjustment factors. For cases where innovative drugs within the medical insurance catalogue are used rationally, medical institutions are supported to independently report individual cases for which payment is inappropriate according to disease type standards. Local health insurance departments should simplify procedures and optimize procedures, organize experts to review individual special cases on a quarterly or monthly basis, and implement project-based payments or adjust payment standards for the relevant cases based on the review results. Designated medical institutions, medical institutions with work-related injury insurance agreements, and work-related injury rehabilitation agreement agencies should, in principle, hold a pharmaceutical council meeting before the end of February 2026 to promptly adjust drug supplies or establish temporary procurement green channels as needed to protect clinical diagnosis and treatment needs and patients' rights to use medication rationally. According to the requirements of the “Certain Measures” and “Notice on Adapting to the Normalization of National Health Insurance Negotiations and Continuing to Accomplish the Implementation of Negotiated Drugs”, negotiated drugs may not be subject to “one product, two regulations”, and must not influence the implementation of negotiated drugs on the grounds of total medical insurance limits, restrictions on the number of drugs used in medical institutions, etc. All regions are encouraged to take active measures to promote negotiated drugs and connect them with designated pharmaceutical institutions.